The development of paliperidone nanocrystals for the treatment of schizophrenia
1
Issued Date
2025-01-01
Resource Type
eISSN
25161091
Scopus ID
2-s2.0-85216079811
Journal Title
Progress in Biomedical Engineering
Volume
7
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Progress in Biomedical Engineering Vol.7 No.1 (2025)
Suggested Citation
Lhaglham P., Jiramonai L., Liang X.J., Liu B., Li F. The development of paliperidone nanocrystals for the treatment of schizophrenia. Progress in Biomedical Engineering Vol.7 No.1 (2025). doi:10.1088/2516-1091/ad8fe7 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/106683
Title
The development of paliperidone nanocrystals for the treatment of schizophrenia
Author(s)
Author's Affiliation
Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College
Peking University Third Hospital
National Center for Nanoscience and Technology Beijing
University of Chinese Academy of Sciences
Mahidol University
Ministry of Education of the People's Republic of China
Peking University Third Hospital
National Center for Nanoscience and Technology Beijing
University of Chinese Academy of Sciences
Mahidol University
Ministry of Education of the People's Republic of China
Corresponding Author(s)
Other Contributor(s)
Abstract
Schizophrenia is a complex and chronic psychiatric disorder that significantly impacts patients’ quality of life. Ranking 12th among 310 diseases and injuries that result in disability, the number of patients suffering from schizophrenia continues to rise, emphasizing the urgent need for developing effective treatments. Despite the availability of effective antipsychotic drugs, over 80% of patients taking oral antipsychotics experience relapses, primarily caused by non-adherence as the high dosing frequency is required. In this review, we discuss about schizophrenia, its incidence, pathological causes, influencing factors, and the challenges of the current medications. Specifically, we explore nanocrystal technology and its application to paliperidone, making it one of the most successful long-acting antipsychotic drugs introduced to the market. We highlight the clinical advantages of paliperidone nanocrystals, including improved adherence, efficacy, long-term outcomes, patient satisfaction, safety, and cost-effectiveness. Additionally, we address the physicochemical factors influencing the drug’s half-life, which crucially contribute to long-acting medications. Further studies on nanocrystal-based long-acting medications are crucial for enhancing their effectiveness and reliability. The successful development of paliperidone nanocrystals holds great promise as a significant approach for drug development, with potential applications for other chronic disease management.